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dTATE-OF-THE-ART PAPER2117Intracardiac Imagingusan S. Kim, Ziyad M. Hijazi, Roberto M. Lang, Bradley P. Knight
im and colleagues review the use of intracardiac echocardiography and other invasive
maging modalities, such as transesophageal echocardiography, intracardiac endoscopy, and
lectroanatomic mapping systems. This review describes the features of an ideal intracardiac
maging tool and reviews the modalities that are currently available or under development.
he use of intracardiac imaging to guide selected cardiac procedures, including transseptal
atheterization, catheter ablation procedures, and percutaneous placement of cardiac valves, is
iscussed.TATE-OF-THE-ART PAPER2129The Cardiac Effects of CKDGFR
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Stiffnessadi G. Hage, Rajesh Venkataraman, Gilbert J. Zoghbi, Gilbert J. Perry, Angelo M. DeMattos,
mi E. Iskandrian
his review by Hage and colleagues outlines the relationship between chronic kidney disease
CKD) and coronary heart disease. As renal function deteriorates, certain physiologic changes
ccur including decreased oxygen-carrying capacity secondary to anemia and blood vessel
tiffening, which raises blood pressure and increases shear stress. CKD may also alter theGenetic Factors Conventional & Other constituents of atherosclerotic plaque and the balance between thrombogenesis and
hrombolysis. The etiology of these changes and possible therapeutic options are reviewed.CLINICAL RESEARCH ORONARY ARTERY DISEASE2141New Technique for Understanding Coronary Collateral DevelopmentEditorial Comment
Ronald W. Millard,tephan H. Schirmer, Niels van Royen, Perry D. Moerland, Joost O. Fledderus, José P. Henriques,
ené J. van der Schaaf, Marije M. Vis, Jan Baan, Jr, Karel T. Koch, Anton J. G. Horrevoets,
mo E. Hoefer, Jan J. Piek
chirmer and colleagues used an export catheter to collect localized blood samples from subjects
ho had coronary stenoses with varying degrees of collateral formation. Proximal coronary flow
as blocked and blood was then withdrawn into the catheter from across the collateral bed. There
as no rise in lactate or change in pH across the collateral bed, suggesting that there was no
schemia in this area. Several cytokines were locally increased, especially in patients with the least
eveloped collateral circulation. This technique allows for detailed analysis not only of the efficiencyYigang Wang, p. 2148 of the collateral circulation but also of factors that stimulate collateral growth.(continued on page A-19)
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rEART FAILURE2150Nebivolol Improves Outcomes in the Elderly With HF, Regardless of EFEditorial Comment
Paul W. Armstrong,irk J. van Veldhuisen, Alain Cohen-Solal, Michael Böhm, Stefan D. Anker, Daphne Babalis,
ichael Roughton, Andrew J. S. Coats, Philip A. Poole-Wilson, Marcus D. Flather, on behalf of the
ENIORS Investigators
n this pre-specified subgroup analysis of the SENIORS trial, which randomized subjects
ver age 70 years with heart failure (HF) to either nebivolol or placebo, van Veldhuisen and
olleagues compared the outcomes for patients with impaired ejection fraction (EF) (35%)
r preserved EF. During 21 months of follow-up, the primary end point (all-cause mortality
r cardiovascular hospitalization) occurred in approximately one-third of subjects for both
reserved and impaired EF. Nebivolol reduced the incidence of the primary end point
imilarly in both groups. In this study of elderly patients with HF, nebivolol improved
utcomes to a similar degree regardless of the baseline EF.EART FAILURE2162Impaired Platelet Aggregation in LVAD Patients Caused by Reduced vWF ActivityHM II HTx CHF Warfarin
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) olanta Klovaite, Finn Gustafsson, Svend A. Mortensen, Kåre Sander, Lars B. Nielsen
ystemic anticoagulation is necessary for patients who receive a mechanical left ventricular
ssist device (LVAD) such as the HeartMate II (HMII); however, there seems to be an
ncreased bleeding tendency in these patients. Klovaite and colleagues hypothesized that the
MII may expose the blood to high shear stress, which could induce proteolysis of von
illebrand factor (vWF) multimers. vWF-dependent platelet aggregation was decreased in
ost HMII patients. This impairment normalized in the patients who subsequently went ono heart transplantation, further suggesting that the HMII device was the causative factor.EART RHYTHM DISORDERS
2168ncidence of Traumatic Tricuspid
Regurgitation After Percutaneous Ventricular Lead Removalrédéric Franceschi, Franck Thuny, Roch Giorgi, Islem Sanaa, Eric Peyrouse, Xavier Assouan,
ébastien Prévôt, Emilie Bastard, Gilbert Habib, Jean-Claude Deharo
amage to the tricuspid valve may occur during percutaneous lead removal, but the incidence
f, risk factors for, and clinical outcomes of traumatic tricuspid regurgitation (TTR) are not
nown. Franceschi and colleagues performed a systematic evaluation including routine pre-
nd post-procedure echocardiography for over 200 percutaneous lead removal procedures.
TR occurred in 9% of patients. During follow-up, there was a trend toward higher
ortality in TTR patients, and most patients with TTR required either medical therapy for
ight-sided heart failure or surgical repair.(continued on page A-24)
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iASCULAR DISEASE AND DIABETES
2175iabetic Patients With Microvascular Complications
Have Impaired Skeletal Muscle Capillary RecruitmentEditorial Commentisa Womack, Dawn Peters, Eugene J. Barrett, Sanjiv Kaul, Wendie Price, Jonathan R. Lindner
oth insulin and exercise increase blood flow and insulin transport in skeletal muscle.
omack and colleagues measured capillary blood flow (CBF) in the forearm muscles using
ltrasound and intravenous echocardiographic contrast in patients with type 2 diabetes
ellitus (DM) with and without microvascular complications (MC). Muscle capillary
esponses to exercise were similar between the control and DM groups, but were reduced in
hose with DM MC, where there was a 60% to 70% reduction in CBF. Capillary
ecruitment during exercise is impaired in diabetic patients with MC.IOMARKERS2186Relationships Between and Oxidized Lipoprotein and Cardiovascular Risk Factorslexander E. Fraley, Gregory G. Schwartz, Anders G. Olsson, Scott Kinlay, Michael Szarek, Nader Rifai,
eter Libby, Peter Ganz, Joseph L. Witztum, Sotirios Tsimikas, for the MIRACL Study Investigators
tatin therapy has been associated with increases in the levels of oxidized phospholipids
OxPL) on apolipoprotein B (apoB) and with reductions in apoB particles resulting in a high
xPL/apoB ratio. Fraley and colleagues delved further into this phenomenon by studying the
nter-relationships between oxidative biomarkers and clinical and demographic factors for
ubjects enrolled in the MIRACL trial. There was a significant increase in OxPL/apoB with
torvastatin in all 20 demographic subgroups evaluated. The consistent increase in OxPL/
poB with atorvastatin suggests that it may be a useful biomarker for the efficacy of various
nterventions on reducing cardiovascular outcomes.
